Five things for pharma marketers to know: Wednesday, August 2, 2017

Share this content:

1. Celgene and Agios Pharmaceuticals received FDA approval for oral drug Idhifa to treat acute myeloid leukemia. Its monthly list price will be $24,872, with a median therapy time of less than five months, Celgene said. (Reuters)

2. GlaxoSmithKline appointed Karenann Terrell to the newly created role of chief digital and technology officer, effective in September. Terrell was most recently chief information officer of Walmart. (PMLive)

3. Pfizer CEO Ian Read said the there needs to be tax reform before the company engages in any deals. The drugmaker missed second-quarter revenue estimates due in part to a drop in sales in older drugs like pneumonia vaccine Prevnar and the loss of exclusivity for Viagra and other drugs. (Bloomberg)

4. WPP's Grey Group promoted Michael Houston to the post of global CEO. He replaces Jim Heekin, who is now executive chairman of the agency. (AdWeek)

5. Daiichi Sankyo agreed to pay $300 million to settle 2,300 cases claiming that it did not warn that blood pressure drug Benicar could cause gastrointestinal illness. (Reuters)

Share this content:
Scroll down to see the next article